STOCK TITAN

CTS (NYSE: CTS) lifts 2025 margins and sets 2026 EPS guidance

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

CTS Corporation reported stronger results for the fourth quarter and full year 2025, driven by growth in diversified industrial, medical, and aerospace & defense markets and better profitability. Fourth-quarter sales were $137.3 million, up 9% year over year, with diversified end markets up 16% and transportation down 1%. Net earnings rose to $19.7 million, and diluted EPS increased to $0.67 from $0.38, helped by higher gross and EBITDA margins.

For full-year 2025, sales reached $541.3 million, up 5%, while net earnings grew to $65.3 million and diluted EPS to $2.19 from $1.80. Diversified end markets grew 16% and represented 57% of revenue, partially offsetting a 7% decline in transportation revenue. Adjusted gross margin improved to 38.5% and adjusted EBITDA margin to 22.8%. Operating cash flow was $102.1 million and free cash flow $86.4 million, supporting $62 million returned to shareholders in 2025.

For 2026, CTS guides revenue of $550–$580 million and adjusted diluted EPS of $2.30–$2.45, assuming continued growth in diversified markets and softness in commercial-vehicle-related sales, with an expected tax rate of 21–23% excluding discrete items.

Positive

  • Stronger profitability and earnings growth: 2025 net sales rose to $541.3 million (+5%), net earnings to $65.3 million, and diluted EPS to $2.19 from $1.80, with Q4 EPS jumping to $0.67 from $0.38.
  • Margin expansion and cash generation: Adjusted gross margin improved to 38.5% and adjusted EBITDA margin to 22.8% for 2025, while operating cash flow reached $102.1 million and free cash flow $86.4 million.
  • Diversified end-market strength and constructive guidance: Diversified markets grew 16% and reached 57% of 2025 revenue, and 2026 guidance calls for $550–$580 million in sales and adjusted EPS of $2.30–$2.45.

Negative

  • None.

Insights

CTS delivered margin-rich growth in 2025 and set moderately higher 2026 guidance, led by diversified end markets.

CTS showed healthy operating leverage in 2025. Net sales rose to $541.3 million, up 5%, while net earnings increased to $65.3 million and diluted EPS to $2.19 from $1.80. Mix shift toward industrial, medical, and aerospace & defense, which now account for 57% of revenue, supported higher margin performance.

Profitability improved across key metrics. Adjusted gross margin expanded to 38.5% from 37.0%, and adjusted EBITDA margin edged up to 22.8% from 22.4%. Q4 results were particularly strong, with net earnings of $19.7 million versus $11.6 million and diluted EPS of $0.67. Solid free cash flow of $86.4 million and reduced long-term debt to $57.5 million strengthened the balance sheet.

Management’s 2026 outlook signals continued, though measured, growth. Revenue guidance of $550–$580 million implies low- to mid-single-digit top-line growth, with adjusted diluted EPS expected between $2.30–$2.45. Assumptions include ongoing softness in commercial-vehicle-related transportation sales and a tax rate of 21–23% excluding discrete items, while diversified markets remain the primary growth engine.

0000026058false00000260582026-02-102026-02-10

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 10, 2026

 

 

CTS CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Indiana

1-4639

35-0225010

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(I.R.S. Employer
Identification No.)

 

 

 

 

 

4925 Indiana Avenue

 

Lisle, Illinois

 

60532

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (630) 577-8800

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, no par value

 

CTS

 

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


 

Item 2.02 Results of Operations and Financial Condition.

On February 10, 2026, CTS Corporation (the "Company") issued a press release providing certain results for the fourth quarter and full-year ended December 31, 2025, as more fully described in the press release. A copy of the press release is attached hereto as Exhibit 99.l and is incorporated by reference herein.

The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.l hereto, is being "furnished" to the Securities and Exchange Commission and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing made by the Company under the Securities Act of 1933 (the “Securities Act”) or the Exchange Act, except as set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

As disclosed in the press release furnished as Exhibit 99.1, the Company will hold a live web cast on February 10, 2026, relating to the Company's financial results for the fourth quarter and full-year ended December 31, 2025. A copy of the slides to be presented during the Company's web cast and discussed in the conference call relating to such financial results is being furnished as Exhibit 99.2 to this Current Report on Form 8-K.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.2 shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing made by the Company under the Securities Act or the Exchange Act, except as set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

 

Description

99.1

 

Earnings Release dated February 10, 2026

99.2

 

Slides of CTS Corporation, 4th Quarter and Full-Year 2025, dated February 10, 2026

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL Document)

 

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 10, 2026

 

CTS CORPORATION

 

 

 

 

By:

/s/ Ashish Agrawal

 

 

Ashish Agrawal

 

 

Vice President and Chief Financial Officer

 

 

 

 

 

 


Exhibit 99.1

img192797187_0.jpg

 

 

February 10, 2026

FOR IMMEDIATE RELEASE

 

 

CTS Announces Fourth Quarter and Full Year 2025 Results

Strong Growth in Diversified Markets and Solid Operational Execution

Lisle, Ill. - CTS Corporation (NYSE: CTS), a leading global designer and manufacturer of highly engineered solutions that “Sense, Connect and Move,” today announced fourth quarter and full year 2025 results.

“CTS delivered another quarter of strong performance, with diversified end-market sales up 16% year over year, and closed 2025 with solid results. Diversified end-markets now represent 57% of revenue, demonstrating progress on our strategic priorities” said Kieran O’Sullivan, CEO of CTS Corporation. “Our teams executed well driving profitable growth, margin expansion, and strong cash generation. We expanded our product offering in the transportation market and had a solid quarter of new business awards. Diversification remains central to our strategy as we continue to strengthen our growth and quality of earnings.”

Fourth Quarter 2025 Results

 

Sales were $137 million in the fourth quarter of 2025, up 9% year-over-year. Sales to diversified end markets increased 16%. Sales to the transportation end market declined 1%.
Net income was $20 million, or 14.4% of sales, compared to $12 million, or 9.1% of sales in the fourth quarter of 2024.
Diluted EPS was $0.67, up 29 cents from $0.38 in the fourth quarter of 2024.
Adjusted Gross margin was 39.1%, up 150 bps from 37.6% in the fourth quarter of 2024.
Adjusted EBITDA margin was 23.7%, up 50 bps from 23.2% in the fourth quarter of 2024.
Adjusted diluted EPS was $0.62, up 12 cents from $0.50 in the fourth quarter of 2024.
Operating cash flow was $29 million, up $4 million from $25 million in the fourth quarter of 2024.

 

Full-Year 2025 Results

 

Sales were $541 million, up 5% year-over-year. Sales to diversified end markets increased 16%. Sales to the transportation end market decreased 7%.
Net income was $65 million, or 12.1% of sales, compared to $56 million, or 10.8% of sales.
Diluted EPS was $2.19, up 39 cents from $1.80 in 2024.
Adjusted Gross margin was 38.5%, up 150 bps from 37.0% in 2024.
Adjusted EBITDA margin was 22.8%, up 40 bps from 22.4% in 2024.
Adjusted diluted EPS was $2.23, up 11 cents from $2.12 in 2024.
Operating cash flow was $102 million, up $4 million from $98 million in 2024.

www.ctscorp.com


 

 

2026 Guidance

CTS expects full-year 2026 sales to be in the range of $550-$580 million and adjusted diluted EPS to be in the range of $2.30-$2.45.

CTS does not provide reconciliations of forward-looking non-GAAP financial measures, such as estimated adjusted diluted earnings per share, to the most comparable GAAP financial measures on a forward-looking basis because CTS is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of certain items, such as, but not limited to, restructuring costs, environmental remediation costs, acquisition-related costs, foreign exchange rates and other non-routine costs. Each of such adjustments has not yet occurred, are out of CTS' control and/or cannot be reasonably predicted. For the same reasons, CTS is unable to address the probable significance of the unavailable information.

 

Conference Call and Supplemental Materials

As previously announced, CTS has scheduled a conference call for 10:00 a.m. (ET) today. The dial-in numbers for access from the U.S. are: +1-833-470-1428 (Toll-Free) and +1-646-844-6383 (Local), if calling from outside the U.S., please refer to Global Dial In Numbers to identify the applicable dial-in number for your location. The passcode is 815166. In addition, CTS will be using a supplemental slide presentation that will be referred to during the call. The presentation and a live audio webcast of the conference call will be available and can be accessed directly from CTS’ website at https://investors.ctscorp.com/news-events/events-and-presentations/.

Any replay, rebroadcast, transcript or other reproduction or transmission of this conference call, other than the replay accessible through the website noted above, has not been authorized by CTS and is strictly prohibited. Investors should be aware that any unauthorized reproduction of this conference call may not be an accurate reflection of its contents.

About CTS

CTS Corporation (NYSE: CTS) is a leading designer and manufacturer of products that Sense, Connect and Move. CTS manufactures sensors, actuators and electronic components in North America, Europe and Asia, and provides engineered products to customers in the aerospace & defense, industrial, medical and transportation markets. For more information, visit www.ctscorp.com/.

Diversified end markets, previously referred as the “non-transportation” market, includes the industrial, aerospace & defense, and medical end markets.

www.ctscorp.com

 


 

 

Cautionary Statement Regarding Forward-Looking Statements

Readers are cautioned that the statements contained in this document regarding expectations of our performance or other matters that may affect our business, results of operations, or financial condition are, or may be deemed to be, “forward-looking statements” as defined by the “safe harbor” provisions in the Private Securities Litigation Reform Act of 1995. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, included or incorporated in this document, including statements regarding our strategy, financial position, guidance, funding for continued operations, cash reserves, liquidity, projected costs, plans, projects, awards and contracts, and objectives of management, among others, are forward-looking statements. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “continued,” “project,” “plan,” “goals,” “opportunity,” “appeal,” “estimate,” “potential,” “predict,” “demonstrates,” “may,” “will,” “might,” “could,” “intend,” “shall,” “possible,” “would,” “approximately,” “likely,” “outlook,” “schedule,” “on track,” “poised,” “pipeline,” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are not guarantees of future performance, conditions or results. Forward-looking statements are based on management’s expectations, certain assumptions, and currently available information. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and are based on various assumptions as to future events, the occurrence of which necessarily are subject to uncertainties. These forward-looking statements are made subject to certain risks, uncertainties, and other factors, which could cause CTS’ actual results, performance, or achievements to differ materially from those presented in the forward-looking statements. Examples of factors that may affect future operating results and financial condition include, but are not limited to: supply chain disruptions (including, but not limited to, the availability and cost of rare earth elements, minerals and metals); changes in the economy generally, including inflationary and/or recessionary conditions and increased tariffs, and in respect to the business in which CTS operates; unanticipated issues in integrating acquisitions; the funding of contracts by the U.S. Government; the results of actions to reposition CTS’ business; rapid technological change; general market conditions in the transportation, as well as conditions in the industrial, aerospace and defense, and medical markets; reliance on key customers; unanticipated public health crises, natural disasters or other events; environmental compliance and remediation expenses; the ability to protect CTS’ intellectual property; pricing pressures and demand for CTS’ products; risks associated with CTS’ international operations, including trade and tariff barriers, exchange rates and political and geopolitical risks (including, without limitation, the impact of tariffs on China, Canada and Mexico, and other nations, the potential impact of U.S./China relations and the impact of geopolitical conflicts may have on our business, results of operations and financial condition; write offs of goodwill on our balance sheet; the amount and timing of any share repurchases; and the effect of any cybersecurity incidents on our business. Many of these, and other risks and uncertainties, are discussed in further detail in Item 1A. of CTS' most recent Annual Report on Form 10-K and other filings made with the SEC. CTS undertakes no obligation to publicly update CTS’ forward-looking statements to reflect new information or events or circumstances that arise after the date hereof, including market or industry changes. 

Contact

Ashish Agrawal

Vice President and Chief Financial Officer

CTS Corporation

4925 Indiana Avenue

Lisle, IL 60532 USA

+1 (630) 577-8800

ashish.agrawal@ctscorp.com

 


 


 


 

www.ctscorp.com

 


 

 

CTS CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS - UNAUDITED

(In thousands, except per share amounts)

 

 

 

 

Three Months Ended

 

 

Twelve Months Ended

 

 

 

December 31,
2025

 

 

December 31,
2024

 

 

December 31,
2025

 

 

December 31,
2024

 

Net sales

 

$

137,271

 

 

$

126,459

 

 

$

541,318

 

 

$

514,756

 

Cost of goods sold

 

 

83,565

 

 

 

79,556

 

 

 

333,292

 

 

 

327,201

 

Gross margin

 

 

53,706

 

 

 

46,903

 

 

 

208,026

 

 

 

187,555

 

Selling, general and administrative expenses

 

 

24,798

 

 

 

22,184

 

 

 

98,720

 

 

 

88,285

 

Research and development expenses

 

 

5,853

 

 

 

5,670

 

 

 

25,268

 

 

 

23,388

 

Restructuring charges

 

 

367

 

 

 

1,040

 

 

 

1,396

 

 

 

4,697

 

Operating earnings

 

 

22,688

 

 

 

18,009

 

 

 

82,642

 

 

 

71,185

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(911

)

 

 

(1,294

)

 

 

(4,309

)

 

 

(4,236

)

Interest income

 

 

531

 

 

 

482

 

 

 

2,134

 

 

 

4,282

 

Other income (expense), net

 

 

2,640

 

 

 

(1,890

)

 

 

3,304

 

 

 

(2,650

)

Total other income (expense) , net

 

 

2,260

 

 

 

(2,702

)

 

 

1,129

 

 

 

(2,604

)

Earnings before income taxes

 

 

24,948

 

 

 

15,307

 

 

 

83,771

 

 

 

68,581

 

Income tax expense

 

 

5,211

 

 

 

3,745

 

 

 

18,454

 

 

 

13,109

 

Net earnings

 

$

19,737

 

 

$

11,562

 

 

$

65,317

 

 

$

55,472

 

Earnings per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.68

 

 

$

0.38

 

 

$

2.21

 

 

$

1.82

 

Diluted

 

$

0.67

 

 

$

0.38

 

 

$

2.19

 

 

$

1.80

 

Basic weighted – average common shares outstanding:

 

 

28,945

 

 

 

30,082

 

 

 

29,508

 

 

 

30,408

 

Effect of dilutive securities

 

 

309

 

 

 

350

 

 

 

298

 

 

 

309

 

Diluted weighted – average common shares outstanding:

 

 

29,254

 

 

 

30,432

 

 

 

29,806

 

 

 

30,717

 

Cash dividends declared per share

 

$

0.04

 

 

$

0.04

 

 

$

0.16

 

 

$

0.16

 

 

 

 

 

 

 

www.ctscorp.com

 


 

 

CTS CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED

(In thousands of dollars)

 

 

 

December 31,
 2025

 

 

December 31, 2024

 

ASSETS

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

Cash and cash equivalents

 

$

82,295

 

 

$

94,334

 

Accounts receivable, net

 

 

88,096

 

 

 

77,649

 

Inventories, net

 

 

52,854

 

 

 

52,312

 

Other current assets

 

 

29,461

 

 

 

17,879

 

Total current assets

 

 

252,706

 

 

 

242,174

 

Property, plant and equipment, net

 

 

89,741

 

 

 

94,357

 

Operating lease assets, net

 

 

22,542

 

 

 

22,939

 

Other Assets

 

 

 

 

 

 

Goodwill

 

 

209,611

 

 

 

201,304

 

Other intangible assets, net

 

 

153,562

 

 

 

163,882

 

Deferred income taxes

 

 

25,110

 

 

 

27,591

 

Other assets

 

 

11,039

 

 

 

13,180

 

Total other assets

 

 

399,322

 

 

 

405,957

 

Total Assets

 

$

764,311

 

 

$

765,427

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

Accounts payable

 

$

48,220

 

 

$

42,629

 

Accrued payroll and benefits

 

 

3,453

 

 

 

4,719

 

Operating lease obligations

 

 

20,732

 

 

 

15,754

 

Accrued expenses and other liabilities

 

 

37,283

 

 

 

35,361

 

Total current liabilities

 

 

109,688

 

 

 

98,463

 

Long-term debt

 

 

57,500

 

 

 

92,300

 

Long-term operating lease obligations

 

 

21,841

 

 

 

21,120

 

Long-term pension obligations

 

 

3,698

 

 

 

3,931

 

Deferred income taxes

 

 

12,800

 

 

 

12,743

 

Other long-term obligations

 

 

6,998

 

 

 

8,662

 

Total Liabilities

 

 

212,525

 

 

 

237,219

 

Commitments and Contingencies

 

 

 

 

 

 

Shareholders’ Equity

 

 

 

 

 

 

Common stock

 

 

324,982

 

 

 

321,979

 

Additional contributed capital

 

 

43,303

 

 

 

44,662

 

Retained earnings

 

 

713,467

 

 

 

652,851

 

Accumulated other comprehensive loss

 

 

13,748

 

 

 

(4,266

)

Total shareholders’ equity before treasury stock

 

 

1,095,500

 

 

 

1,015,226

 

Treasury stock

 

 

(543,714

)

 

 

(487,018

)

Total shareholders’ equity

 

 

551,786

 

 

 

528,208

 

Total Liabilities and Shareholders’ Equity

 

$

764,311

 

 

$

765,427

 

 

www.ctscorp.com

 


 

 

CTS CORPORATION AND SUBSIDIARIES

OTHER SUPPLEMENTAL INFORMATION - UNAUDITED

(In millions of dollars, except percentages and per share amounts)

Non-GAAP Financial Measures

From time to time, CTS may use non-GAAP financial measures in discussing CTS’ business. These measures are intended to supplement, not replace, CTS’ presentation of its financial results in accordance with U.S. GAAP. CTS believes that the non-GAAP financial measures presented are commonly used by financial analysts and others in the industries in which CTS operates, and thus further provide useful information to investors. CTS’ definitions of these non-GAAP financial measures may differ from those terms as defined or used by other companies. Non-GAAP measures should not be used by investors or third parties as the sole basis for formulating investment decisions, as they may exclude a number of important cash and non-cash recurring items.

CTS has presented these non-GAAP financial measures as it believes that the presentation of its financial results that exclude (1) restructuring charges; (2) restructuring-related charges; (3) environmental charges; (4) acquisition-related adjustments; (5) inventory fair value step-up costs; (6) foreign exchange (gains) losses; (7) non-cash pension expenses (income); and (8) certain discrete tax items are useful and assist in comparing CTS’ current operating results with past periods and with the operational performance of other companies in its industry. Included below is a description of the expenses that CTS has determined are not normal, recurring cash operating expenses necessary to operate its business and the rationale for why providing financial measures for its business with such expenses excluded or adjusted is useful to investors as a supplement to the U.S. GAAP measures.

Restructuring charges – costs primarily relating to workforce reduction costs, building and equipment relocation costs, asset impairment charges and other facility closure costs in connection with our continued optimization of our organization.
Restructuring-related charges – costs related to restructuring actions that do not qualify as direct restructuring charges under US GAAP. These include duplicative expenses incurred due to the plant consolidation related transition activities such as excess rent, utilities, personnel related and other costs prior to start of production at the new location.
Environmental charges – costs associated with our non-operating facilities that are unrelated to ongoing operations. Currently, none of these costs and accruals relate to sites that provide revenue generating activities for the Company.
Acquisition-related adjustments – diligence and transaction costs related to acquisitions including related contingent earnout and other adjustments.
Inventory fair value step-up costs – purchase accounting-related inventory costs from acquisitions.
Foreign exchange (gains) losses – remeasurement income and expenses for non-U.S. subsidiaries with the U.S. dollar as the functional currency.
Non-cash pension expenses (income) – pension income and expenses relating to the non-operating U.S. pension and post-retirement life insurance plans, including historical plan settlement activities.
Discrete tax items – non-recurring, infrequent, or unusual tax adjustments (e.g., valuation allowances, uncertain tax position changes, unremitted assertion changes and discrete impacts associated with pre-tax non-GAAP items or due to tax law changes, etc.).

At times, the reconciliations below have been intentionally rounded to the nearest thousand, or $0.01 for EPS figures, and, therefore, may not sum.

www.ctscorp.com

 


 

 

 

Adjusted Gross Margin

 

 

Three Months Ended
December 31,

 

 

Twelve Months Ended
December 31,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

 

2023

 

Gross margin

 

$

53.7

 

 

$

46.9

 

 

$

208.0

 

 

$

187.6

 

 

$

190.9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$

137.3

 

$

126.5

 

$

541.3

 

 

$

514.8

 

 

$

550.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross margin as a % of net sales

 

 

39.1

%

 

 

37.1

%

 

 

38.4

%

 

 

36.4

%

 

 

34.7

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjustments to reported gross margin:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring-related charges (b)

 

 

 

 

 

 

 

 

0.2

 

 

 

0.7

 

 

 

0.6

 

Inventory fair value step-up (b)

 

 

 

 

 

0.7

 

 

 

 

 

 

2.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted gross margin

 

$

53.7

 

$

47.6

 

$

208.2

 

 

$

190.4

 

 

$

191.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted gross margin as a % of net sales

 

 

39.1

%

 

 

37.6

%

 

38.5

%

 

 

37.0

%

 

 

34.8

%

 

 


 

 

Adjusted Operating Earnings

 

 

Three Months Ended
December 31,

 

 

Twelve Months Ended
December 31,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

 

2023

 

Operating earnings

 

$

22.7

 

 

$

18.0

 

 

$

82.6

 

 

$

71.2

 

 

$

75.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$

137.3

 

 

$

126.5

 

 

$

541.3

 

 

$

514.8

 

 

$

550.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating earnings as a % of net sales

 

 

16.5

%

 

 

14.2

%

 

 

15.3

%

 

 

13.8

%

 

 

13.6

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjustments to reported operating earnings:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring charges (c)

 

 

0.4

 

 

 

1.0

 

 

 

1.4

 

 

 

4.7

 

 

 

7.1

 

Restructuring-related charges (b)

 

 

0.4

 

 

 

 

 

 

0.7

 

 

 

0.7

 

 

 

0.6

 

Environmental charges (a)

 

 

0.8

 

 

 

1.9

 

 

 

5.5

 

 

 

1.6

 

 

 

3.5

 

Acquisition-related adjustments (a)

 

 

(0.8

)

 

 

(1.0

)

 

 

(3.4

)

 

 

(0.3

)

 

 

0.4

 

Inventory fair value step-up (b)

 

 

 

 

 

0.7

 

 

 

 

 

 

2.1

 

 

 

 

Total adjustments to reported operating earnings

 

$

0.7

 

 

$

2.6

 

 

$

4.2

 

 

$

8.8

 

 

$

11.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted operating earnings

 

$

23.4

 

 

$

20.7

 

 

$

86.9

 

 

$

80.0

 

 

$

86.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted operating earnings as a % of net sales

 

 

17.1

%

 

 

16.3

%

 

 

16.0

%

 

 

15.5

%

 

 

15.7

%

 

 


 

 

Adjusted EBITDA Margin

 

 

Three Months Ended
December 31,

 

 

Twelve Months Ended
December 31,

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

 

2023

 

Net earnings

 

$

19.7

 

 

$

11.6

 

 

$

65.3

 

 

$

55.5

 

 

$

60.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$

137.3

 

 

$

126.5

 

 

$

541.3

 

 

$

514.8

 

 

$

550.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings margin

 

 

14.4

%

 

 

9.1

%

 

 

12.1

%

 

 

10.8

%

 

 

11.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Depreciation and amortization expense

 

 

8.7

 

 

 

8.2

 

 

 

34.5

 

 

 

30.9

 

 

 

28.7

 

 Interest expense

 

 

0.9

 

 

 

1.3

 

 

 

4.3

 

 

 

4.2

 

 

 

3.3

 

 Tax expense

 

 

5.2

 

 

 

3.7

 

 

 

18.5

 

 

 

13.1

 

 

 

14.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EBITDA

 

 

34.6

 

 

 

24.8

 

 

 

122.6

 

 

 

103.7

 

 

 

107.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EBITDA Margin

 

 

25.2

%

 

 

19.6

%

 

 

22.6

%

 

 

20.1

%

 

 

19.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjustments to EBITDA:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Restructuring charges (c)

 

 

0.4

 

 

 

1.0

 

 

 

1.4

 

 

 

4.7

 

 

 

7.1

 

 Restructuring-related charges (b)

 

 

0.4

 

 

 

 

 

 

0.7

 

 

 

0.7

 

 

 

0.6

 

 Environmental charges (a)

 

 

0.8

 

 

 

1.9

 

 

 

5.5

 

 

 

1.6

 

 

 

3.5

 

 Acquisition-related adjustments (a)

 

 

(3.0

)

 

 

(1.0

)

 

 

(5.6

)

 

 

(0.3

)

 

 

0.4

 

 Inventory fair value step-up (b)

 

 

 

 

 

0.7

 

 

 

 

 

 

2.1

 

 

 

 

 Non-cash pension and related expense (d)

 

 

0.0

 

 

 

0.0

 

 

 

0.1

 

 

 

0.2

 

 

 

 

 Foreign currency (gain) loss (d)

 

 

(0.5

)

 

 

1.9

 

 

 

(1.3

)

 

 

2.7

 

 

 

2.0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total adjustments to EBITDA

 

 

(2.0

)

 

 

4.6

 

 

 

0.9

 

 

 

11.7

 

 

 

13.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

$

32.6

 

 

$

29.4

 

 

$

123.4

 

 

$

115.4

 

 

$

120.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA Margin

 

 

23.7

%

 

 

23.2

%

 

 

22.8

%

 

 

22.4

%

 

 

21.9

%

 

 


 

 

Adjusted Net Earnings and Adjusted Diluted Earnings Per Share

 

 

Three Months Ended
December 31,

 

 

 

2025

 

 

2025

 

 

2024

 

 

2024

 

 

 

 

 

 

Per share

 

 

 

 

 

Per share

 

Net earnings (A)

 

$

19.7

 

 

$

0.67

 

 

$

11.6

 

 

$

0.38

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjustments to reported net earnings:

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring charges (c)

 

 

0.4

 

 

 

0.01

 

 

 

1.0

 

 

 

0.03

 

Restructuring-related charges (a)

 

 

0.4

 

 

 

0.01

 

 

 

 

 

 

 

Environmental charges (a)

 

 

0.8

 

 

 

0.03

 

 

 

1.9

 

 

 

0.06

 

Acquisition-related adjustments (a)

 

 

(3.0

)

 

 

(0.10

)

 

 

(1.0

)

 

 

(0.03

)

Inventory fair value step-up (b)

 

 

 

 

 

 

 

 

0.7

 

 

 

0.02

 

Non-cash pension and related expense (d)

 

 

0.0

 

 

 

0.00

 

 

 

0.0

 

 

 

0.00

 

Foreign currency (gain) loss (d)

 

 

(0.5

)

 

 

(0.02

)

 

 

1.9

 

 

 

0.06

 

Total pretax adjustments to reported net earnings

 

$

(2.0

)

 

$

(0.07

)

 

$

4.6

 

 

$

0.15

 

Income tax effect of above adjustments (f)

 

 

0.4

 

 

 

0.01

 

 

 

(0.8

)

 

 

(0.03

)

Total adjustments, tax affected (f) (B)

 

$

(1.6

)

 

$

(0.05

)

 

$

3.8

 

 

$

0.12

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Other discrete tax items (e)

 

 

 

 

 

 

 

 

 

 

 

 

Total tax adjustments (C)

 

$

 

 

$

 

 

$

 

 

$

 

Adjusted net earnings (A+B+C) and Adjusted net earnings per share

 

$

18.2

 

 

$

0.62

 

 

$

15.3

 

 

$

0.50

 

 

 

 

 

 

 

 

 

Net sales

 

$

137.3

 

 

 

 

 

$

126.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings as a % of net sales

 

 

14.4

%

 

 

 

 

 

9.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted net earnings as a % of net sales

 

 

13.2

%

 

 

 

 

 

12.1

%

 

 

 

 

 


 

 

 

 

 

Twelve Months Ended
December 31,

 

 

 

2025

 

 

2025

 

 

2024

 

 

2024

 

 

2023

 

 

2023

 

 

 

 

 

 

Per share

 

 

 

 

 

Per share

 

 

 

 

 

Per share

 

Net earnings (loss) (A)

 

$

65.3

 

 

$

2.19

 

 

$

55.5

 

 

$

1.80

 

 

$

60.5

 

 

$

1.92

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjustments to reported net earnings:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring charges (c)

 

 

1.4

 

 

 

0.05

 

 

 

4.7

 

 

 

0.15

 

 

 

7.1

 

 

 

0.22

 

Restructuring-related charges (a)

 

 

0.7

 

 

 

0.02

 

 

 

0.7

 

 

 

0.02

 

 

 

0.6

 

 

 

0.02

 

Environmental charges (a)

 

 

5.5

 

 

 

0.18

 

 

 

1.6

 

 

 

0.05

 

 

 

3.5

 

 

 

0.11

 

Acquisition-related adjustments (a)

 

 

(5.6

)

 

 

(0.19

)

 

 

(0.3

)

 

 

(0.01

)

 

 

0.4

 

 

 

0.01

 

Inventory fair value step-up (b)

 

 

 

 

 

 

 

 

2.1

 

 

 

0.07

 

 

 

 

 

 

 

Non-cash pension and related expense (d)

 

 

0.1

 

 

 

0.00

 

 

 

0.2

 

 

 

0.01

 

 

 

 

 

 

 

Foreign currency loss (d)

 

 

(1.3

)

 

 

(0.04

)

 

 

2.7

 

 

 

0.09

 

 

 

2.0

 

 

 

0.06

 

Total pretax adjustments to reported net earnings

 

$

0.9

 

 

$

0.03

 

 

$

11.7

 

 

$

0.38

 

 

$

13.5

 

 

$

0.42

 

Income tax effect of above adjustments (f)

 

 

(0.6

)

 

 

(0.02

)

 

 

(2.2

)

 

 

(0.07

)

 

 

(2.4

)

 

 

(0.07

)

Total adjustments, tax affected (f) (B)

 

$

0.3

 

 

$

0.01

 

 

$

9.5

 

 

$

0.31

 

 

$

11.1

 

 

$

0.35

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Increase in valuation allowances (e)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other discrete tax items (e)

 

 

0.8

 

 

 

0.03

 

 

 

0.3

 

 

 

0.01

 

 

 

(1.6

)

 

 

(0.05

)

Total tax adjustments (C)

 

$

0.8

 

 

$

0.03

 

 

$

0.3

 

 

$

0.01

 

 

$

(1.6

)

 

$

(0.05

)

Adjusted net earnings (A+B+C) and Adjusted net earnings per share

 

$

66.3

 

 

$

2.23

 

 

$

65.3

 

 

$

2.12

 

 

$

70.0

 

 

$

2.22

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$

541.3

 

 

 

 

 

$

514.8

 

 

 

 

 

$

550.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings as a % of net sales

 

 

12.1

%

 

 

 

 

 

10.8

%

 

 

 

 

 

11.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted net earnings as a % of net sales

 

 

12.3

%

 

 

 

 

 

12.7

%

 

 

 

 

 

12.7

%

 

 

 

 

(a) Reflected in Selling, general and administrative and other income (expense), net.
(b) Reflected in Cost of goods sold.
(c) Reflected in Restructuring charges.

(d) Reflected in Other income (expense), net.

 


 

 

(e) Reflected in Income tax expense. For 2023, discrete tax items include adjusting for tax benefits resulting from $0.6 million for research and development tax credits from prior years, $0.8 million in foreign tax credits related to prior years from a 2023 tax law change, as well as $0.2 million from the release of uncertain tax benefits. For 2024, the discrete tax items relate to items we deemed outside normal cash-generating operations including the addition of a valuation allowance for a foreign subsidiary. For 2025, the discrete tax items relate to items we deemed outside normal cash-generating operations including the addition of a valuation allowance for research and developmental credits and the tax impacts of an immaterial correction of a prior period error.

(f) We determine the tax effect of non-GAAP adjustments by considering the tax laws and statutory income tax rates applicable in the tax jurisdictions of the underlying non-GAAP adjustments. For all periods presented, we applied the statutory income tax rates to the taxable portion of all of our adjustments. Our acquisition costs and foreign currency gains and losses included in our non-GAAP adjustments were not deductible for income tax purposes; therefore, no statutory income tax rate was applied to such costs.

 

 

NOTE: CTS believes that adjusted gross margin, adjusted operating earnings, adjusted EBITDA margin, adjusted net earnings and adjusted diluted earnings per share provide useful information to investors regarding its operational performance because they enhance an investor’s overall understanding of CTS’ core financial performance and facilitate comparisons to historical results of operations, by excluding items that are not related directly to the underlying performance of CTS’ fundamental business operations (such as those items noted above in the paragraph titled “Non-GAAP Financial Measures”) or were not part of CTS’ business operations during a comparable period.

 

Controllable Working Capital

 

 

December 31,

 

 

 

2025

 

 

2024

 

 

2023

 

Net accounts receivable

 

$

88.1

 

 

$

77.6

 

 

$

78.6

 

 

 

 

 

 

 

 

 

 

 

Net inventory

 

$

52.9

 

 

$

52.3

 

 

$

60.0

 

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

$

(48.2

)

 

$

(42.6

)

 

$

(43.5

)

 

 

 

 

 

 

 

 

 

 

Controllable working capital

 

$

92.7

 

 

$

87.3

 

 

$

95.1

 

 

 

 

 

 

 

 

 

 

 

Quarter sales

 

$

137.3

 

 

$

126.4

 

 

$

124.7

 

Multiplied by 4

 

 

4

 

 

 

4

 

 

 

4

 

Annualized sales

 

$

549.1

 

 

$

505.6

 

 

$

498.8

 

 

 

 

 

 

 

 

 

 

 

Controllable working capital as a % of annualized sales

 

 

16.9

%

 

 

17.3

%

 

 

19.1

%

NOTE: CTS believes the controllable working capital ratio is a useful measure because it provides an objective measure of the efficiency with which CTS manages its short-term capital needs.

 

 


 

 

Free Cash Flow

 

 

Three Months Ended
December 31,

 

 

Twelve Months Ended
December 31,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

 

2023

 

Net cash provided by operating activities

 

$

29.2

 

 

$

25.0

 

 

$

102.1

 

 

$

98.2

 

 

$

88.8

 

Capital expenditures

 

 

(3.2

)

 

 

(6.1

)

 

 

(15.7

)

 

 

(18.6

)

 

 

(14.7

)

Free cash flow

 

$

26.0

 

 

$

18.9

 

 

$

86.4

 

 

$

79.6

 

 

$

74.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating cash flow as a percentage of net earnings

 

 

148

%

 

 

216

%

 

 

156

%

 

 

177

%

 

 

147

%

Free cash flow as a percentage of adjusted net earnings

 

 

143

%

 

 

123

%

 

 

130

%

 

 

122

%

 

 

106

%

NOTE: CTS believes that free cash flow is a useful measure because it demonstrates the company’s ability to generate cash. Free cash flow is a non-GAAP measure and should be considered in addition to, but not as a substitute for, information contained in the company's condensed consolidated statement of cash flows as a measure of liquidity.

 

Capital Expenditures

 

 

Three Months Ended
December 31,

 

 

Twelve Months Ended
December 31,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

 

2023

 

Capital expenditures

 

$

3.2

 

 

$

6.1

 

 

$

15.7

 

 

$

18.6

 

 

$

14.7

 

Net sales

 

$

137.3

 

 

$

126.5

 

 

$

541.3

 

 

$

514.8

 

 

$

550.4

 

Capex as % of net sales

 

 

2.3

%

 

 

4.8

%

 

 

2.9

%

 

 

3.6

%

 

 

2.7

%

 

Additional Information

The following table includes other financial information not presented in the preceding financial statements.

 

 

Three Months Ended
December 31,

 

 

Twelve Months Ended
December 31,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

 

2023

 

Depreciation and amortization expense

 

$

8.7

 

 

$

8.2

 

 

$

34.5

 

 

$

30.9

 

 

$

28.7

 

Stock-based compensation expense

 

$

1.5

 

 

$

1.7

 

 

$

4.9

 

 

$

5.7

 

 

$

5.2

 

The Company updated certain previously furnished 2024 amounts due to immaterial errors identified. Refer to Note 1, "Basis of Presentation" in the Annual Report on Form 10-K as of December 31, 2025 for more information.

 

 


Slide 1

CTS Corporation 4th Quarter and Full-Year 2025 Earnings Call February 10, 2026


Slide 2

Cautionary Statement Regarding Forward-Looking Statements Readers are cautioned that the statements contained in this document regarding expectations of our performance or other matters that may affect our business, results of operations, or financial condition are, or may be deemed to be, “forward-looking statements” as defined by the “safe harbor” provisions in the Private Securities Litigation Reform Act of 1995. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, included or incorporated in this document, including statements regarding our strategy, financial position, guidance, funding for continued operations, cash reserves, liquidity, projected costs, plans, projects, awards and contracts, and objectives of management, among others, are forward-looking statements. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “continued,” “project,” “plan,” “goals,” “opportunity,” “appeal,” “estimate,” “potential,” “predict,” “demonstrates,” “may,” “will,” “might,” “could,” “intend,” “shall,” “possible,” “would,” “approximately,” “likely,” “outlook,” “schedule,” “on track,” “poised,” “pipeline,” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are not guarantees of future performance, conditions or results. Forward-looking statements are based on management’s expectations, certain assumptions, and currently available information. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and are based on various assumptions as to future events, the occurrence of which necessarily are subject to uncertainties. These forward-looking statements are made subject to certain risks, uncertainties, and other factors, which could cause CTS’ actual results, performance, or achievements to differ materially from those presented in the forward-looking statements. Examples of factors that may affect future operating results and financial condition include, but are not limited to: supply chain disruptions (including, but not limited to, the availability and cost of rare earth elements, minerals and metals); changes in the economy generally, including inflationary and/or recessionary conditions and increased tariffs, and in respect to the business in which CTS operates; unanticipated issues in integrating acquisitions; the funding of contracts by the U.S. Government; the results of actions to reposition CTS’ business; rapid technological change; general market conditions in the transportation, as well as conditions in the industrial, aerospace and defense, and medical markets; reliance on key customers; unanticipated public health crises, natural disasters or other events; environmental compliance and remediation expenses; the ability to protect CTS’ intellectual property; pricing pressures and demand for CTS’ products; risks associated with CTS’ international operations, including trade and tariff barriers, exchange rates and political and geopolitical risks (including, without limitation, the impact of tariffs on China, Canada and Mexico, and other nations); the potential impact of U.S./China relations and the impact of geopolitical conflicts may have on our business, results of operations and financial condition; write offs of goodwill on our balance sheet; the amount and timing of any share repurchases; and the effect of any cybersecurity incidents on our business. Many of these, and other risks and uncertainties, are discussed in further detail in Item 1A. of CTS’ most recent Annual Report on Form 10-K and other filings made with the SEC. CTS undertakes no obligation to publicly update CTS’ forward-looking statements to reflect new information or events or circumstances that arise after the date hereof, including market or industry changes. CTS refers to the forward-looking measures of book-to-bill ratio and total booked business in this document. Book-to-bill ratio is the ratio of customer orders received to revenues recorded for the same period. Although the book-to-bill ratio reflects firm customer orders, changes such as terminations, amendments, or contract cancellations may occur which could result in a reduction to the customer orders. Total booked business reflects expected revenue from the remaining life of long-term agreements with transportation customers. Total booked business is adjusted periodically for changes in expected revenue based on market information, fluctuations in foreign currency exchange rates, information from our customers, and any other factors that may impact the expected revenue from these agreements. Book-to-bill ratio and total booked business are not defined by U.S. GAAP and our methodology for calculating these measures may not be consistent with or comparable to other similarly titled measures of other companies.  


Slide 3

Solid growth from diversified end markets2 Revenue +9% for Q4 2025 Revenue +5% for full year 2025 59% of total revenue in Q4 2025 57% of total revenue for full year 2025 Transportation end market challenging Revenue flat for Q4 2025 Revenue (7)% for full year 2025 Lower sales of commercial vehicle products Book-to-bill ratio3 1.04 for full year 2025 Notes: All comparisons vs. same period in prior year unless otherwise noted. 1 Adj. Gross Margin and Adj. Earnings per Share are non-GAAP financial measures. Refer to the Appendix for reconciliations of non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. 2 Diversified end markets, previously referred as the “non-transportation” market, includes the industrial, aerospace & defense, and medical end markets. 3 Refer to slide 2 for information on book-to-bill ratio. Q4 and Full-Year 2025 – Strong Growth in Diversified Markets and Operational Execution $137M Revenue +9% Fourth Quarter 39.1% Adj. Gross Margin1 +150 bps $0.62 Adj. Diluted EPS1 +23% $541M Revenue +5% Full Year 2025 38.5% Adj. Gross Margin1 +150 bps $2.23 Adj. Diluted EPS1 +5%


Slide 4

Medical $85 4 Aerospace & Defense ($ Millions) Revenue $83 ($ Millions) FY 2025 Sales up 21%; book to bill 1.07 Q4 2025 Sales up 41% vs. Q4 2024 Robust growth driven by therapeutic and minimally invasive applications Multiple Q4 wins across all regions in medical ultrasound, therapeutic applications FY 2025 Sales up 20%; book to bill 0.91 Q4 2025 Sales down 4% vs. Q4 2024 SyQwest $22m in revenue in 2025 Wins across naval sonar, hydrophones, RF filters (anti‑jamming and drones) Added three new customers for underwater locator beacons and sonobuoy electronics Revenue End Markets Update


Slide 5

End Markets Update Industrial 1 Refer to slide 2 for information on total booked business. 5 Transportation ($ Millions) FY 2025 Sales up 12%; book to bill 1.11 Q4 Sales up 16% year-over-year Continued recovery from cyclical lows across OEM and distribution customers Multiple Q4 wins across distribution, industrial printing, EMC, temperature sensing FY 2025 down 7% year over year; Q4 sales flat $1b total booked business1 at end of Q4 2025 Added floor hinge pedal technology with a first North American OEM win Multiple platform awards for accelerator modules Continued progress on electronic brake pedal Revenue ($ Millions) Revenue


Slide 6

$2.45 $2.30 Notes:  1 Adjusted Diluted EPS is a non-GAAP financial measure. Refer to the Appendix for reconciliations of non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. FY 2026 Guidance Revenue ($ Millions) Adjusted Diluted EPS 1 $550 $580 Continued progress on growth in diversified end-markets Softness in commercial vehicle-related sales in 2026  Light vehicle 2026 production expected to be flat to slightly down year-over-year Tax rate expected to be in the range of 21-23% excluding discrete items Key Outlook Assumptions


Slide 7

4th Quarter and Full-Year 2025 Financial Results


Slide 8

Notes: All comparisons vs. same period in prior year unless otherwise noted. 1 Adj. Diluted EPS, Adj. Gross Margin and Adj. EBITDA Margin are non-GAAP financial measures. Refer to the Appendix for reconciliations of non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Revenue up 9% vs. Q4 2024 Diversified end market revenues up 16% vs. Q4 2024 SyQwest $6m revenue in Q4 Transportation revenues down 1% year-over-year $2m favorable currency rate impact for Revenue Adjusted Gross Margin +150 bps vs. Q4 2024 Adjusted EBITDA +50 bps vs. Q4 2024 Net Income $11.6 $13.7 $19.7 Diluted EPS $0.38 $0.46 $0.67 Adj. Diluted EPS1 $0.50 $0.60 $0.62 Adj. Gross Margin1 37.6% 38.9% 39.1% Adj. EBITDA Margin1 23.2% 23.8% 23.7% Revenue Q4 2025 Financial Summary Results ($ Millions, except percentages and per share amounts) Highlights


Slide 9

Notes: All comparisons vs. same period in prior year unless otherwise noted. 1 Adj. Diluted EPS, Adj. Gross Margin and Adj. EBITDA Margin are non-GAAP financial measures. Refer to the Appendix for reconciliations of non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Net Income $55.5 $65.3 Diluted EPS $1.80 $2.19 Adj. Diluted EPS1 $2.12 $2.23 Adj. Gross Margin1 37.0% 38.5% Adj. EBITDA Margin1 22.4% 22.8% Full-Year 2025 Financial Summary Results ($ Millions, except percentages and per share amounts) Highlights Revenue up 5% year over year Diversified end market revenues up 16% vs. 2024 SyQwest added $22m in revenue Transportation revenues down 7% Lower commercial vehicle sales and China softness Continued year over year margin expansion Adjusted Gross Margin up 150 bps Adjusted EBITDA up 40 bps $3m favorable currency rate impact on revenue and $2m favorable impact on gross margin Revenue


Slide 10

Cash and Debt1 $62M Cash Returned to Shareholders FY 20253 $86M FY 2025 Free Cash Flow2 Strong Balance Sheet Solid Foundation for Strategic M&A $16M FY 2025 Capital Expenditures Borrowed Total Facility Operating Cash Flow Prioritizing strong cash flow generation ($ Millions) ($ Millions) Notes:  1 Cash and Debt balance as of December 31, 2025 2 Free Cash Flow is a non-GAAP financial measure. Refer to the Appendix for reconciliations of non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. 3 Cash Returned to Shareholders consists of share repurchases & dividends.


Slide 11

Q & A


Slide 12

Appendix


Slide 13

Non-GAAP Financial Measures From time to time, CTS may use non-GAAP financial measures in discussing CTS’ business. These measures are intended to supplement, not replace, CTS’ presentation of its financial results in accordance with U.S. GAAP. CTS believes that the non-GAAP financial measures presented are commonly used by financial analysts and others in the industries in which CTS operates, and thus further provide useful information to investors. CTS’ definitions of these non-GAAP financial measures may differ from those terms as defined or used by other companies. Non-GAAP measures should not be used by investors or third parties as the sole basis for formulating investment decisions, as they may exclude a number of important cash and non-cash recurring items. CTS has presented these non-GAAP financial measures as it believes that the presentation of its financial results that exclude (1) restructuring charges; (2) restructuring-related charges; (3) environmental charges; (4) acquisition-related adjustments; (5) inventory fair value step-up costs; (6) foreign exchange (gains) losses; (7) non-cash pension expenses (income); and (8) certain discrete tax items are useful and assist in comparing CTS’ current operating results with past periods and with the operational performance of other companies in its industry. Included below is a description of the expenses that CTS has determined are not normal, recurring cash operating expenses necessary to operate its business and the rationale for why providing financial measures for its business with such expenses excluded or adjusted is useful to investors as a supplement to the U.S. GAAP measures. Restructuring charges – costs primarily relating to workforce reductions, building and equipment relocations, asset impairment charges and other facility closure activities in connection with our continued optimization of our organization. Restructuring-related charges – costs related to restructuring actions that do not qualify as direct restructuring charges under U.S. GAAP. These include duplicative expenses incurred due to plant consolidation related transition activities such as excess rent, utilities, personnel related and other costs incurred prior to the start of production at the new location.  Environmental charges – costs associated with our non-operating facilities that are unrelated to ongoing operations. Currently, none of these costs and accruals relate to sites that provide revenue generating activities for the Company.  Acquisition-related adjustments – diligence and transaction costs related to acquisitions including related contingent earnout and other adjustments. Inventory fair value step-up costs – purchase accounting-related inventory costs from acquisitions. Foreign exchange (gains) losses – remeasurement income and expenses for non-U.S. subsidiaries with the U.S. dollar as the functional currency. Non-cash pension expenses (income) – pension income and expenses relating to the non-operating U.S. pension and post-retirement life insurance plans, including historical plan settlement activities. Discrete tax items – non-recurring, infrequent, or unusual tax adjustments (e.g., valuation allowances, uncertain tax position changes, unremitted assertion changes and discrete impacts associated with pre-tax non-GAAP items or due to tax law changes, etc.). At times, the reconciliations below have been intentionally rounded to the nearest thousand, or $0.01 for EPS figures, and, therefore, may not sum. CTS does not provide reconciliations of forward-looking non-GAAP financial measures, such as estimated adjusted diluted earnings per share, to the most comparable GAAP financial measures on a forward-looking basis because CTS is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of certain items, such as, but not limited to, restructuring costs, environmental remediation costs, acquisition-related costs, foreign exchange rates and other non-routine costs. Each of such adjustments has not yet occurred, are out of CTS' control and/or cannot be reasonably predicted. For the same reasons, CTS is unable to address the probable significance of the unavailable information. The Company updated certain previously furnished 2024 amounts due to immaterial errors identified. Refer to Note 1, "Basis of Presentation" in the Annual Report on Form 10-K as of December 31, 2025 for more information.


Slide 14

Regulation G Schedules ($ Millions, except percentages) Adjusted Gross Margin Three Months Ended December 31, Three Months Ended September 30, Twelve Months Ended December 31, 2025 2024 2025 2025 2024 2023 Gross margin $ 53.7   $ 46.9   $ 55.3 $ 208.0   $ 187.6   $ 190.9 Net sales   $ 137.3   $ 126.5   $ 143.0   $ 541.3   $ 514.8   $ 550.4 Gross margin as a % of net sales 39.1%   37.1%   38.7%   38.4%   36.4%   34.7% Adjustments to reported gross margin:                       Restructuring-related charges (b) — — 0.2 0.2 0.7 0.6 Inventory fair value step-up (b) —   0.7   —   —   2.1   — Adjusted gross margin   $ 53.7   $ 47.6   $ 55.6   $ 208.2   $ 190.4   $ 191.4   Adjusted gross margin as a % of net sales   39.1%   37.6%   38.9%   38.5%   37.0%   34.8%


Slide 15

Regulation G Schedules ($ Millions, except percentages) Adjusted Operating Earnings Three Months Ended December 31, Twelve Months Ended December 31, 2025 2024 2025 2024 2023 Operating earnings $ 22.7   $ 18.0 $ 82.6   $ 71.2   $ 75.1 Net sales $ 137.3   $ 126.5 $ 541.3   $ 514.8   $ 550.4 Operating earnings as a % of net sales 16.5%   14.2% 15.3%   13.8%   13.6% Adjustments to reported operating earnings:                 Restructuring charges (c) 0.4 1.0 1.4 4.7 7.1 Restructuring-related charges (b) 0.4   — 0.7   0.7   0.6 Environmental charges (a) 0.8 1.9 5.5 1.6 3.5 Acquisition-related adjustments (a) (0.8)   (1.0) (3.4)   (0.3)   0.4 Inventory fair value step-up (b) — 0.7 — 2.1 — Total adjustments to reported operating earnings $ 0.7   $ 2.6 $ 4.2   $ 8.8   $ 11.5 Adjusted operating earnings $ 23.4   $ 20.7 $ 86.9   $ 80.0   $ 86.6 Adjusted operating earnings as a % of net sales 17.1%   16.3% 16.0%   15.5%   15.7%


Slide 16

Regulation G Schedules ($ Millions, except percentages) Adjusted EBITDA Margin Three Months Ended December 31, Three Months Ended September 30, Twelve Months Ended December 31, 2025 2024 2025 2025 2024 2023 Net earnings (loss) $ 19.7   $ 11.6   $ 13.7   $ 65.3   $ 55.5   $ 60.5 Net sales $ 137.3   $ 126.5   $ 143.0   $ 541.3   $ 514.8   $ 550.4 Net earnings (loss) margin 14.4%   9.1%   9.6%   12.1%   10.8%   11.0% Depreciation and amortization expense 8.7   8.2   8.8   34.5   30.9   28.7 Interest expense 0.9 1.3 1.1 4.3 4.2 3.3 Tax expense (benefit) 5.2   3.7   6.0   18.5   13.1   14.6 EBITDA 34.6   24.8   29.7   122.6   103.7   107.2 EBITDA Margin 25.2%   19.6%   20.7%   22.6%   20.1%   19.5% Adjustments to EBITDA:                       Restructuring charges (c) 0.4 1.0 0.3 1.4 4.7 7.1 Restructuring related charges (b) 0.4   —   0.4   0.7   0.7   0.6 Environmental charges (a) 0.8 1.9 4.2 5.5 1.6 3.5 Acquisition-related costs (a) (3.0)   (1.0)   (1.1)   (5.6)   (0.3)   0.4 Inventory fair value step-up (b) — 0.7 — — 2.1 — Non-cash pension and related expense (d) 0.0   0.0   0.0   0.1   0.2   — Foreign currency (gain) loss (d) (0.5) 1.9 0.6 (1.3) 2.7 2.0                       Total adjustments to EBITDA (2.0) 4.6 4.4 0.9 11.7 13.5                       Adjusted EBITDA $ 32.6 $ 29.4 $ 34.1 $ 123.4 $ 115.4 $ 120.7                       Adjusted EBITDA Margin 23.7% 23.2% 23.8% 22.8% 22.4% 21.9%


Slide 17

Regulation G Schedules ($ Millions, except percentages and per share amounts) Adjusted Net Earnings and Adjusted Diluted Earnings Per Share Three Months Ended December 31, Three Months Ended September 30, 2025 2025 2024 2024 2025 2025 Per share Per share Net earnings (A) $ 19.7   $ 0.67   $ 11.6   $ 0.38   $ 13.7   $ 0.46 Adjustments to reported net earnings:                       Restructuring charges (c) 0.4 0.01 1.0 0.03 0.3 0.01 Restructuring related charges (a) 0.4   0.01   —   —   0.4   0.01 Environmental charges (a) 0.8 0.03 1.9 0.06 4.2 0.14 Acquisition-related costs (a) (3.0)   (0.10)   (1.0)   (0.03)   (1.1)   (0.03) Inventory fair value step-up (b) — — 0.7 0.02 — — Non-cash pension and related expense (d) 0.0   0.00   0.0   0.00   0.0   — Foreign currency (gain) loss (d) (0.5) (0.02) 1.9 0.06 0.6 0.02 Total pretax adjustments to reported net earnings $ (2.0)   $ (0.07)   $ 4.6   $ 0.15   $ 4.4   $ 0.15 Income tax effect of above adjustments (f) 0.4 0.01 (0.8) (0.03) (1.0) (0.03) Total adjustments, tax affected (f) (B) $ (1.6)   $ (0.05)   $ 3.8   $ 0.12   $ 3.4   $ 0.12 Tax adjustments:                       Other discrete tax items (e) — — — — 0.7 0.0 Total tax adjustments (C) $ —   $ —   $ —   $ —   $ 0.7   $ 0.02 Adjusted net earnings (A+B+C) and Adjusted net earnings per share $ 18.2 $ 0.62 $ 15.3 $ 0.50 $ 17.8 $ 0.60           Net sales $ 137.3 $ 126.5 $ 143.0                       Net earnings as a % of net sales 14.4% 9.1% 9.6%                       Adjusted net earnings as a % of net sales 13.2% 12.1% 12.4%


Slide 18

Regulation G Schedules ($ Millions, except percentages and per share amounts) Adjusted Net Earnings and Adjusted Diluted Earnings Per Share NOTE: CTS believes that adjusted gross margin, adjusted operating earnings, adjusted EBITDA margin, adjusted net earnings and adjusted diluted earnings per share provide useful information to investors regarding its operational performance because they enhance an investor’s overall understanding of CTS’ core financial performance and facilitate comparisons to historical results of operations, by excluding items that are not related directly to the underlying performance of CTS’ fundamental business operations (such as those items noted above in the paragraph titled “Non-GAAP Financial Measures”) or were not part of CTS’ business operations during a comparable period. Twelve Months Ended December 31, 2025 2025 2024 2024 2023 2023 2022 2022 Per share Per share Per share Per share Net earnings (loss) (A) $ 65.3   $ 2.19   $ 55.5   $ 1.80   $ 60.5   $ 1.92   $ 59.6   $ 1.85 Adjustments to reported net earnings (loss):                               Restructuring charges (c) 1.4 0.05 4.7 0.15 7.1 0.22 1.9 0.06 Restructuring related charges (a) 0.7   0.02   0.7   0.02   0.6   0.02   —   — Environmental charges (a) 5.5 0.18 1.6 0.05 3.5 0.11 2.8 0.09 Acquisition-related adjustments (a) (5.6)   (0.19)   (0.3)   (0.01)   0.4   0.01   2.5   0.08 Inventory fair value step-up (b) — — 2.1 0.07 — — 4.0 0.12 Non-cash pension and related expense (d) 0.1   0.00   0.2   0.01   —   —   4.8   0.15 Foreign currency loss (d) (1.3) (0.04) 2.7 0.09 2.0 0.06 4.9 0.15 Total pretax adjustments to reported net earnings (loss) $ 0.9   $ 0.03   $ 11.7   $ 0.38   $ 13.5   $ 0.42   $ 20.9   $ 0.65 Income tax effect of above adjustments (f) (0.6) (0.02) (2.2) (0.07) (2.4) (0.07) (1.6) (0.05) Total adjustments, tax affected (f) (B) $ 0.3   $ 0.01   $ 9.5   $ 0.31   $ 11.1   $ 0.35   $ 19.3   $ 0.60 Tax adjustments:                               Increase in valuation allowances (e) — — — — — - Other discrete tax items (e) 0.8   0.03   0.3   0.01   (1.6)   (0.05)   0.2   0.01 Total tax adjustments (C) $ 0.8 $ 0.03 $ 0.3 $ 0.01 $ (1.6) $ (0.05) $ 0.2 $ 0.01 Adjusted net earnings (A+B+C) and Adjusted Net Earnings Per Share $ 66.3   $ 2.23   $ 65.3   $ 2.12   $ 70.0   $ 2.22   $ 79.1   $ 2.46 Net sales $ 541.3       $ 514.8       $ 550.4       $ 586.9     Net earnings (loss) as a % of net sales 12.1%       10.8%       11.0%       10.2%     Adjusted net earnings as a % of net sales 12.3%       12.7%       12.7%       13.5%    


Slide 19

Reflected in Selling, general and administrative and other income (expense), net. Reflected in Cost of goods sold. Reflected in Restructuring charges. Reflected in Other income (expense), net. Reflected in Income tax expense. For 2023, discrete tax items include adjusting for tax benefits resulting from $0.6 million for research and development tax credits from prior years, $0.8 million in foreign tax credits related to prior years from a 2023 tax law change, as well as $0.2 million from the release of uncertain tax benefits. For 2024, the discrete tax items relate to items we deemed outside normal cash-generating operations including the addition of a valuation allowance for a foreign subsidiary. For 2025, the discrete tax items relate to items we deemed outside normal cash-generating operations including the addition of a valuation allowance for research and developmental credits, the tax impacts of an immaterial correction of a prior period error, the tax impacts related to cost associated with the environmental contamination liability. We determine the tax effect of non-GAAP adjustments by considering the tax laws and statutory income tax rates applicable in the tax jurisdictions of the underlying non-GAAP adjustments. For all periods presented, we applied the statutory income tax rates to the taxable portion of all of our adjustments. Our acquisition costs and foreign currency gains and losses included in our non-GAAP adjustments were not deductible for income tax purposes; therefore, no statutory income tax rate was applied to such costs. Regulation G Schedules


Slide 20

($ Millions, except percentages) Free Cash Flow ($ Millions, except percentages) Controllable Working Capital NOTE: CTS believes the controllable working capital ratio is a useful measure because it provides an objective measure of the efficiency with which CTS manages its short-term capital needs. NOTE: CTS believes that free cash flow is a useful measure because it demonstrates the company’s ability to generate cash. Free cash flow is a non-GAAP measure and should be considered in addition to, but not as a substitute for, information contained in the company's condensed consolidated statement of cash flows as a measure of liquidity. Regulation G Schedules December 31, 2025 2024 2023 Net accounts receivable $ 88.1   $ 77.6   $ 78.6 Net inventory $ 52.9   $ 52.3   $ 60.0 Accounts payable $ (48.2)   $ (42.6)   $ (43.5) Controllable working capital $ 92.7   $ 87.3   $ 95.1 Quarter sales $ 137.3   $ 126.4   $ 124.7 Multiplied by 4 4 4 4 Annualized sales $ 549.1   $ 505.6   $ 498.8 Controllable working capital as a % of annualized sales 16.9%   17.3%   19.1% Three Months Ended December 31, Twelve Months Ended December 31, 2025 2024 2025 2024 2023 Net cash provided by operating activities $ 29.2 $ 25.0 $ 102.1 $ 98.2 $ 88.8 Capital expenditures (3.2) (6.1) (15.7) (18.6) (14.7) Free cash flow $ 26.0 $ 18.9 $ 86.4 $ 79.6 $ 74.1 Operating cash flow as a percentage of net earnings 148%   216%   156%   177%   147% Free cash flow as a percentage of adjusted net earnings 143% 123% 130% 122% 106%

FAQ

How did CTS (CTS) perform financially in the fourth quarter of 2025?

CTS posted solid Q4 2025 growth, with revenue of $137.3 million, up 9% year over year. Net earnings rose to $19.7 million from $11.6 million, and diluted EPS increased to $0.67 from $0.38, supported by a 39.1% adjusted gross margin and 23.7% adjusted EBITDA margin.

What were CTS (CTS) full-year 2025 revenue and earnings results?

For 2025, CTS generated revenue of $541.3 million and net earnings of $65.3 million. Sales grew 5% versus 2024, while diluted EPS rose to $2.19 from $1.80. Adjusted diluted EPS was $2.23, and margins improved, with adjusted gross margin at 38.5% and adjusted EBITDA margin at 22.8%.

How did CTS (CTS) diversified and transportation end markets perform in 2025?

Diversified end markets were the main growth driver for CTS in 2025. Sales to diversified industrial, aerospace & defense, and medical markets increased 16% and reached 57% of total revenue. Transportation revenue declined 7% for the year, reflecting weaker commercial vehicle demand and China softness.

What 2026 guidance did CTS (CTS) provide for revenue and earnings?

CTS expects modest growth in 2026, with revenue guidance of $550–$580 million. The company forecasts adjusted diluted EPS between $2.30 and $2.45, assuming continued diversified end-market growth, softness in commercial-vehicle-related sales, and a tax rate of 21–23% excluding discrete items.

How strong was CTS (CTS) cash flow and balance sheet in 2025?

CTS produced robust cash generation in 2025, with operating cash flow of $102.1 million. Free cash flow reached $86.4 million, and capital expenditures were $15.7 million. Long-term debt declined to $57.5 million, and the company returned $62 million to shareholders through dividends and share repurchases.

What non-GAAP metrics does CTS (CTS) emphasize and why?

CTS highlights adjusted gross margin, adjusted operating earnings, adjusted EBITDA, and adjusted diluted EPS. These measures exclude items like restructuring, environmental charges, acquisition-related costs, inventory fair value step-up, foreign exchange effects, non-cash pension items, and discrete tax items to better reflect underlying operating performance.

Filing Exhibits & Attachments

3 documents
CTS Corp

NYSE:CTS

CTS Rankings

CTS Latest News

CTS Latest SEC Filings

CTS Stock Data

1.55B
28.44M
Electronic Components
Printed Circuit Boards
Link
United States
LISLE